Emerging therapies for breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• HER2 and Cyclin-Dependent Kinase 4/6 (CDK4/6) are critical biological targets in breast cancer treatment.
• Current anti-HER2 therapies demonstrate benefits in objective response, progression-free survival (PFS), disease-free survival (DFS), and overall survival (OS).
• CDK4/6 inhibitors have consistently shown improvements in objective response and PFS, but their impact on overall survival is still under investigation.

Purpose of the Study:

• To review the current landscape of biological targets in breast cancer, focusing on HER2 and CDK4/6.
• To evaluate the efficacy of existing and emerging therapeutic strategies targeting these pathways.
• To identify unmet needs and future directions in breast cancer treatment optimization.

Main Methods:

• Literature review of clinical trials and research studies on HER2-targeted therapies and CDK4/6 inhibitors.
• Analysis of efficacy data including objective response rate (ORR), PFS, DFS, and OS.
• Exploration of novel treatment combinations and strategies for breast cancer management.

Main Results:

• Anti-HER2 treatments are established to improve key survival and response metrics.
• Three CDK4/6 inhibitors have demonstrated consistent improvements in ORR and PFS.
• Further data are required to confirm the overall survival benefits of CDK4/6 inhibitors.
• Optimization of chemotherapy and endocrine therapy remains an important clinical challenge.
• Immunotherapy, particularly checkpoint inhibitors combined with chemotherapy, shows promise, especially for triple-negative breast cancer.

Conclusions:

• HER2 and CDK4/6 pathways represent validated targets for breast cancer therapy.
• While significant progress has been made, further research is needed to fully elucidate the long-term survival benefits of CDK4/6 inhibitors.
• Combining immunotherapy with chemotherapy presents a promising avenue for treating specific breast cancer subtypes, such as triple-negative breast cancer.